In the context of the ongoing outbreak of Shiga toxin-producing E. coli (STEC) that affects by now citizens from 13 EU member states, it is crucial not only to align the efforts regarding investigation and control of the outbreak but also to share knowledge among practitioners across Europe on the patho-physiological and clinical characteristics of infection caused by this unusual epidemic strain, and review patient management options.
In his speech before the EU Health Ministers recently, ECDC Director Marc Sprenger outlined several public health measures to meet the measles elimination target by 2015 in Luxembourg.
Today, the German authorities published a press release on the current Shiga toxin-producing E.coli outbreak. In their joint statement they recommended in particular to abstain from eating raw sprouts.
ECDC and WHO Europe jointly release “MESSAGE - MEaSles and rubella Self Assessment GEnerating tool” for public health experts, to facilitate assessment of the progress made towards measles and rubella elimination.
Artemisinin resistance in falciparum malaria has emerged in western Cambodia exactly where chloroquine resistance arose 50 years ago. Similarly to the resistance to chloroquine that spread to Africa, the experts are wondering whether artemisinin resistance will spread as widely. In such a case the consequences would be disastrous.
The authors describe a case of imported Plasmodium knowlesi infection in a French tourist acquired in Thailand. The patient had spent a three month beach holiday on the west coast of Thailand including a one month stay on the Island of Ko Payam.
Using surveillance data obtained from 21,888 imported Plasmodium falciparum cases in France during 1996-2003, factors independently associated with severe malaria (832 cases; ≈3.8%) were older age, European origin, travel to eastern Africa, absence of chemoprophylaxis, initial visit to a general practitioner, time to diagnosis of 4 to 12 days, and diagnosis during the fall-winter season.
This study describes the outcome of 25 travellers with severe malaria who returned from malaria-endemic regions and were treated at 7 centres in Europe with intravenous artesunate. Among these 25 patients, one child and 24 adults (mean ± SD age 44.1 ± 16.1 years), 10 patients received the dosing regimen for artesunate initially recommended by WHO and 11 received artesunate, 2.4 mg/kg/dose.
The overall objective is to improve early detection and response to outbreak of zoonotic diseases at the EU level through strengthened collaboration with the animal health sector and other agencies and organizations working at the animal-human interface.